Prospective Explore of Clinical-Pathological Shrinkage Modes After Neoadjuvant Therapy in Breast Cancer

Zhao Bi, Zhao-Peng Zhang, Cheng-Jun Xu, Peng Chen, Pengfei Qiu, Tong Zhao, Yongsheng WangResearch 2021 · DOI

Abstract

Purpose: This study aimed to explore clinical-pathological shrinkage modes oriented toward breast-conserving surgery (BCS) after neoadjuvant therapy (NAT) using three-dimensional (3D) MRI and pathology reconstruction. Methods: 104 breast cancer patients were prospectively studied between 2014 and 2018. 3D MRI and pathology models were reconstructed to assess residual tumor patterns. Shrinkage modes were categorized into clinical pathological-concentric (CP-CSM) and non-concentric (CP-NCSM). Results: 3D MRI reconstruction predicted shrinkage modes with 93.3% accuracy. Independent predictors included primary tumor stage, malignant calcification, molecular subtypes, and nodal down-staging. Patients with CP-CSM showed significantly better survival outcomes. Conclusion: 3D MRI reconstruction and the developed nomogram provide a reliable tool for guiding individualized BCS selection.

Introduction

Neoadjuvant therapy (NAT) is increasingly used to downstage breast cancer, potentially converting patients from mastectomy candidates to breast-conserving surgery (BCS) candidates. However, the safety of BCS depends heavily on the pattern of tumor regression. While "concentric" shrinkage (CP-CSM) allows for clear surgical margins, "non-concentric" shrinkage (CP-NCSM)—characterized by scattered residual "islands" of cancer—poses a high risk of local recurrence. Traditional 2D imaging often fails to accurately map these complex 3D residual volumes. This study utilizes 3D MRI and pathological reconstruction to better define these shrinkage modes and predict surgical outcomes.

Methods and Patient Cohort

The study prospectively enrolled 104 female patients at the Shandong Cancer Hospital Breast Cancer Center. The cohort's baseline characteristics, including molecular subtypes and clinical stages, are summarized in the table below.

Table 1: Baseline clinical and pathological characteristics of the study cohort (N=104).

3D Reconstruction and Classification

Patients underwent MRI before and after NAT. 3D-DOCTOR software was used to build volumetric models from MRI data. Post-surgery, residual tumors were analyzed via sub-serial sectioning (5mm slices) to create a "gold standard" 3D pathology model.

Shrinkage was classified into:

  • CP-CSM (Concentric): Residual tumor diameter <50% of the primary tumor and ≤2cm.
  • CP-NCSM (Non-concentric): All other patterns, including multinodular or diffuse residual lesions.

Results

Predictive Accuracy of 3D MRI

The 3D MRI reconstruction demonstrated high performance in predicting clinical-pathological shrinkage modes, achieving an accuracy of 93.3%, sensitivity of 97.0%, and specificity of 86.5% (Kappa = 0.850).

Independent Predictors and Nomogram

Multivariate analysis identified four independent predictors of shrinkage mode:

  1. Primary tumor stage (OR=2.059)
  2. Mammographic malignant calcification (OR=3.424)
  3. Molecular subtype (OR=0.530)
  4. Nodal down-staging after NAT (OR=0.183)

A nomogram incorporating these factors achieved an Area Under the Curve (AUC) of 0.833, indicating strong predictive power for identifying candidates suitable for BCS.

Survival Outcomes

With a median follow-up of 77 months, the CP-CSM group exhibited a significantly lower recurrence/metastasis rate (7.1%) compared to the CP-NCSM group (29.4%, p=0.002). Both overall survival (OS) and disease-free survival (DFS) were significantly improved in the CP-CSM group.

Discussion

The integration of 3D MRI reconstruction provides a more nuanced understanding of tumor response to NAT than traditional diameter-based measurements. By identifying patients likely to undergo concentric shrinkage, surgeons can more confidently recommend BCS even in cases that might have previously been deemed high-risk.

While the results are promising, the study's single-center nature and the technical complexity of 3D pathological reconstruction are limitations. Future multi-center trials are necessary to validate the nomogram for broader clinical application. This approach represents a significant step toward personalized surgical planning in breast cancer treatment.

Summary updated

Abstract

Abstract Purpose: The aim was to explore the clinical-pathological shrinkage modes which oriented by breast conserving surgery (BCS) purpose after neoadjuvant therapy (NAT) using three-dimensional (3D) MRI and pathology reconstruction, in order to guide the individualized selection of BCS candidates and scope of resection after NAT. Methods: From April 2014 to 2018, 104 breast cancer patients underwent operation after NAT were included in this prospective study. All patients underwent MRI examinations before and after NAT. Breast residual tumors were prepared with sub-serial section. The 3D MRI and pathology models were reconstructed with 3D-DOCTOR software. The association and correlation between 3D MRI and pathology models were assessed. The traditional shrinkage modes included the surgical pathology complete response, solitary lesions without surrounding lesions, multinodular lesions, solitary lesions with adjacent spotty lesions and diffuse lesions. Combined with the MD Anderson Cancer Center BCS indications after NAT and traditional shrinkage modes, we derived clinical-pathological shrinkage modes which oriented by BCS purpose: clinical pathological-concentric shrinkage modes (CP-CSM) and clinical pathological-non concentric shrinkage modes (CP-NCSM). The CP-CSM means the longest diameter of residual tumor was less than 50% and ≤2cm in comparison with the primary tumor before NAT. Other shrinkage modes were classified as CP-NCSM. Univariate and multivariate logistic regression analysis was conducted to identify the independent predictive factors of clinical-pathological shrinkage modes. A nomogram was developed based on variables in the final model with p &lt;0.05. Results: Based on the gold standard of 3D pathology reconstruction model-measured shrinkage modes, the accuracy, sensitivity and specificity of 3D MRI reconstruction for predicting the traditional shrinkage modes were 84.6%, 61.9% and 90.4%, respectively (Kappa value=0.497). The accuracy, sensitivity and specificity of 3D MRI reconstruction in predicting clinical-pathological shrinkage modes were 93.3%, 97.0% and 86.5%, respectively (Kappa value=0.850). Multivariate analysis showed that primary tumor stage (OR=2.059, 95%CI: 1.187-3.574), mammographic malignant calcification (OR=3.424, 95%CI: 1.437-8.161), molecular subtypes (OR=0.530, 95%CI: 0.364-0.772) and nodal down-staging after NAT (OR=0.183, 95%CI: 0.067-0.497) were independent predictors of clinical-pathological shrinkage modes (all p &lt;0.05). A nomogram was created based on these four predictors. The AUC value was 0.833 (95%CI: 0.710-0.922). The calibration curve showed a satisfactory fit between the predictive and actual observation. With a median follow-up time of 77 months, the recurrence/metastasis rate in the CP-CSM and CP-NCSM group was 7.1% and 29.4%, respectively ( p =0.002). Patients with CP-CSM had a better overall survival and disease-free survival (all p &lt;0.05). Conclusion: The 3D MRI reconstruction after NAT could accurately predict the extent of residual tumor. Combining clinical, imaging, molecular subtypes and NAT efficacy, the nomogram of clinical-pathological shrinkage modes showed sufficient predicting accuracy. And it could help to guide the individualized selection of BCS candidates and scope of resection after NAT, thereby achieve the minimum and effective treatment. However, the applicability of the nomogram still needs to be externally validated. Patients with CP-NCSM after NAT had a worse prognosis.
BibTeX
@inproceedings{bi2021prospective,
  author = {Zhao Bi and Zhao-Peng Zhang and Cheng-Jun Xu and Peng Chen and Pengfei Qiu and Tong Zhao and Yongsheng Wang},
  title = {{Prospective Explore of Clinical-Pathological Shrinkage Modes After Neoadjuvant Therapy in Breast Cancer}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-960396/v1},
}
Figure